Nicoletta D.
- Country
- Italy
- Department
- Ginecology
Research Overview
- Phase 3 Randomized Study of Rinatabart Sesutecan + Bevacizumab vs Bevacizumab in Recurrent Platinum‑Sensitive Ovarian Cancer after Second‑Line Platinum Doublet
- Phase III Randomized Trial of Letrozole Versus Carboplatin and Paclitaxel in Estrogen/Progesterone Receptor-Positive Low-Grade Serous Ovarian Carcinoma
- A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects with TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy
Data & Insights
Has run more than one trial at 44 of 170 partner sites.
Specializations
Gynecologic Oncology
The investigator specializes in treating advanced female reproductive system cancers, with particular focus on endometrial cancer and ovarian carcinoma management strategies.
- Advanced Endometrial Cancer
- Recurrent Endometrial Cancer
- Low-grade Serous Epithelial Ovarian Cancer
The research interests extend to cancers of the fallopian tube and peritoneum, particularly in advanced disease stages.
Targeted Therapies
The investigator focuses on developing targeted treatment approaches for gynecologic cancers, including evaluation of hormone receptor-positive tumors and specific molecular pathways.
- TP53 Wild-Type Cancer Treatment
- Hormone Receptor-Positive Cancer Therapy
- Maintenance Therapy Strategies
Special attention is given to hormone-dependent cancers expressing estrogen and progesterone receptors.
Treatment Innovation
The investigator explores alternative treatment approaches to standard chemotherapy, investigating novel therapeutic agents for gynecologic cancers.
- Advanced Stage Disease Management
- Hormone Therapy Applications
- Progressive Disease Treatment
Research focuses on comparing the effectiveness of targeted therapies against conventional treatment methods.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.